The Dynamo Series is currently available for order in the US, with release anticipated in the first half of 2026.

The Deerfield-based medical device and pharmaceutical company is facing down a balance sheet loaded with debt and business ...

Shares of Baxter International Inc. slid 4.37% to $20.15 Monday, on what proved to be an all-around favorable trading session ...

The Federal Reserve's rate cut historically boosts healthcare stocks, and Baxter International's recent downturn presents a buying opportunity due to overblown market reactions. Baxter's acquisition ...

Baxter International, a global healthcare products company with more than $15 billion in annual revenue, kicked off 2023 with the new year’s resolution of becoming streamlined and nimble. Five months ...

Baxter stock (NYSE: BAX) currently trades at $41 per share, more than 50% lower than the level seen in March 2021, and it can see higher levels over time. BAX stock was trading at around $64 in early ...

Strengths highlight Baxter's robust product portfolio and strategic acquisitions. Weaknesses underscore challenges in cost management and R&D productivity. Opportunities emphasize potential in digital ...

Baxter International Inc. (NYSE:BAX) is one of the most undervalued and overlooked large-cap stocks. On August 4, a Barclays analyst lowered his price target on Baxter International Inc. (NYSE:BAX) to ...

Thousands of jobs at Baxter are potentially on the line as the medtech giant embarks on a cost-cutting plan in the wake of a year that CEO José Almeida said had “disappointed” the company. Alongside ...